StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
FDA Panel 6 YES, 7 NO That Eteplirsen Shows Clinical Benefit (SRPT)
April 25, 2016 6:12 PM
FDA Panel votes 6 YES 7 NO that ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Hot FDA News
Trader Talk
Next Articles
Sarepta Therapeutics (SRPT) Continues Grind Higher from Morning Lows
April 26, 2016 12:45 PM
Piper Jaffray Downgrades Sarepta Therapeutic (SRPT) to Underweight
April 26, 2016 7:28 AM
Sarepta Therapeutic (SRPT) PT Cut to $5 at RBC Capital
April 26, 2016 7:14 AM
Sarepta Therapeutics (SRPT) Resumes Trading; Shares down 53%
April 26, 2016 7:11 AM
Sarepta Therapeutic (SRPT) PT Cut to $7 at Jefferies Following Negative AdCom
April 26, 2016 6:49 AM
Oppenheimer Downgrades Sarepta Therapeutic (SRPT) to Perform
April 26, 2016 6:40 AM
Sarepta Therapeutics (SRPT) Issues Commentary on Adverse FDA Panel Vote for Eeplirsen in DMD
April 26, 2016 5:58 AM
FDA Panel Starts Getting Cautious on Sarepta's (SRPT) Eteplirsen
April 25, 2016 12:19 PM
Sarepta Therapeutics (SRPT) Halted Ahead of FDA AdCom
April 25, 2016 7:02 AM
Sarepta Therapeutics (SRPT) Active Ahead of Today's FDA AdCom and Expected Halt
April 25, 2016 6:40 AM
